Factors Influencing Cancer Patients Participation in Clinical Trials in China.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-15

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research studies factors affecting Chinese patient participation in cancer clinical trials and their knowledge regarding clinical trials. The investigators design this study to determining how patients makes decisions about participating in a clinical trial and know about patients' attitude toward clinical trials. The investigators aim to find ways to make cancer clinical trials in China more efficient and satisfied patients participating in clinical trials in China.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development of a Scale for Cancer Patients' Willingness to Voluntarily Participate in Drug Clinical Trials

NCT06120335

Cancer

RECRUITING

Observational Study of the Decision Making Towards Clinical Trials in Cancer Patients

NCT01341210

Lung Cancer Liver Cancer

UNKNOWN

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

NCT05292521

Lung Non-Small Cell Carcinoma Stage I Lung Cancer AJCC v8 Stage IA1 Lung Cancer AJCC v8 +6 more

RECRUITING NA

Bioinformation Therapy for Lung Cancer

NCT03239171

Small-cell Lung Cancer

COMPLETED PHASE2/PHASE3

Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors

NCT05834413

Lung Cancer

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of malignancy
* Aged 18 years or older
* Ability to understand and complete the questionnaire independently or with the help of a relative or staff member of the oncology department
* Patients have been consented to join an oncology treatment clinical study and have begun active treatment of an oncology clinical trial

Exclusion Criteria

• Not meeting all eligibility criteria

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shi Yuankai

Professor of medical oncology Deputy Director National Cancer Center Vice President Cancer Hospital Chinese Academy of Medical Sciences(CAMS) & Peking Union Medical College(PUMC)

Responsibility Role PRINCIPAL_INVESTIGATOR